Jensen MC - Search Results

1

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW. Till BG, et al. Among authors: jensen mc. Blood. 2012 Apr 26;119(17):3940-50. doi: 10.1182/blood-2011-10-387969. Epub 2012 Feb 3. Blood. 2012. PMID: 22308288 Free PMC article.

2

Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy.

Greenberg PD, Nelson B, Gilbert M, Sing A, Yee C, Jensen M, Riddell SR. Greenberg PD, et al. Ciba Found Symp. 1994;187:212-23; discussion 224-8. doi: 10.1002/9780470514672.ch14. Ciba Found Symp. 1994. PMID: 7796672

3

Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.

Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E, Greenberg PD. Sing AP, et al. Blood. 1997 Mar 15;89(6):1978-86. Blood. 1997. PMID: 9058719 Free article.

4

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.

Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. Jensen M, et al. Biol Blood Marrow Transplant. 1998;4(2):75-83. doi: 10.1053/bbmt.1998.v4.pm9763110. Biol Blood Marrow Transplant. 1998. PMID: 9763110 Free article.

5

Human T lymphocyte genetic modification with naked DNA.

Jensen MC, Clarke P, Tan G, Wright C, Chung-Chang W, Clark TN, Zhang F, Slovak ML, Wu AM, Forman SJ, Raubitschek A. Jensen MC, et al. Mol Ther. 2000 Jan;1(1):49-55. doi: 10.1006/mthe.1999.0012. Mol Ther. 2000. PMID: 10933911 Free article.

6

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.

Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, Jensen MC. Cooper LJ, et al. Among authors: jensen mc. Blood. 2003 Feb 15;101(4):1637-44. doi: 10.1182/blood-2002-07-1989. Epub 2002 Oct 10. Blood. 2003. PMID: 12393484 Free article.

7

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.

Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A. Jensen MC, et al. Cytotherapy. 2003;5(2):131-8. doi: 10.1080/14653240310001028. Cytotherapy. 2003. PMID: 12745575

8

Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production.

Topp MS, Riddell SR, Akatsuka Y, Jensen MC, Blattman JN, Greenberg PD. Topp MS, et al. Among authors: jensen mc. J Exp Med. 2003 Sep 15;198(6):947-55. doi: 10.1084/jem.20021288. Epub 2003 Sep 8. J Exp Med. 2003. PMID: 12963692 Free PMC article.

9

Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.

Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, Laugen C, Raubitschek A, Forman SJ, Jensen MC. Wang J, et al. Among authors: jensen mc. Mol Ther. 2004 Apr;9(4):577-86. doi: 10.1016/j.ymthe.2003.12.011. Mol Ther. 2004. PMID: 15093188 Free article.

10

Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.

Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC. Cooper LJ, et al. Among authors: jensen mc. Blood Cells Mol Dis. 2004 Jul-Aug;33(1):83-9. doi: 10.1016/j.bcmd.2004.03.003. Blood Cells Mol Dis. 2004. PMID: 15223016 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page